<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04332640</url>
  </required_header>
  <id_info>
    <org_study_id>ALPI-101-SYST</org_study_id>
    <nct_id>NCT04332640</nct_id>
  </id_info>
  <brief_title>Clinical Evaluation of the Next Generation Phaco System</brief_title>
  <acronym>ALPINE</acronym>
  <official_title>Clinical Investigation of the Next Generation Phaco System (VERITAS Vision System)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Johnson &amp; Johnson Surgical Vision, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Johnson &amp; Johnson Surgical Vision, Inc.</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is a prospective, open-label clinical study of the VERITAS Vision System.&#xD;
&#xD;
      The study will be conducted at up to three sites, with minimum 55 eyes and up to 150 eyes to&#xD;
      be treated. The investigator or designee will perform the cataract surgery with the VERITAS&#xD;
      Vision System on the subjects. The data from the system log files, the questionnaire, the&#xD;
      operative report and other medical records will be used to assess the clinical utilization of&#xD;
      the VERITAS Vision System.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">September 28, 2020</start_date>
  <completion_date type="Actual">May 1, 2021</completion_date>
  <primary_completion_date type="Actual">May 1, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall clinical performance</measure>
    <time_frame>1 day postoperative</time_frame>
    <description>Overall clinical performance will be evaluated based on surgeon's ratings (Surgeon rating will be on a scale from 1 to 5. Surgeon acceptability will be considered favorable for scores of 4 and 5) and system log files.</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">80</enrollment>
  <condition>Cataract</condition>
  <arm_group>
    <arm_group_label>Next Generation Phaco System</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>VERITAS Vision System</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>VERITAS Vision System</intervention_name>
    <description>The investigators or designees will perform routine small-incision cataract surgery via phacoemulsification and use the VERITAS Vision system. The Investigator or designee will then complete a questionnaire regarding the clinical use of the VERITAS Vision system. The system log files automatically generated by the VERITAS Vision system after completion of each surgery will be collected.</description>
    <arm_group_label>Next Generation Phaco System</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Minimum 22 years of age.&#xD;
&#xD;
          -  Cataracts for which cataract extraction and posterior chamber IOL implantation have&#xD;
             been planned.&#xD;
&#xD;
          -  Availability, willingness, ability and sufficient cognitive awareness to comply with&#xD;
             study requirements, examination procedures, and visits.&#xD;
&#xD;
          -  Be willing to provide informed consent and authorization to disclose protected health&#xD;
             information or equivalent documentation necessary to comply with applicable privacy&#xD;
             laws pertaining to medical procedures in the governing countries.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Expected surgical difficulties at the time of cataract extraction, which may increase&#xD;
             the potential for complications (e.g., persistent bleeding, significant iris damage,&#xD;
             uncontrolled intraocular pressure change, or significant vitreous prolapse or loss).&#xD;
&#xD;
          -  Subjects with only one good eye (e.g. amblyopic condition etc.).&#xD;
&#xD;
          -  Subjects with conditions associated with increased risk of zonular rupture, including&#xD;
             capsular or zonular abnormalities that may lead to IOL decentration, including&#xD;
             pseudoexfoliation, trauma, or posterior capsule defects.&#xD;
&#xD;
          -  History or current use of alpha-1 antagonist medication (e.g., Flomax).&#xD;
&#xD;
          -  Any condition which, in the Investigator's opinion, would make it unsafe (for the&#xD;
             subject or for the study personnel) to treat the subject as part of this research&#xD;
             study or for which cataract surgery is contraindicated.&#xD;
&#xD;
          -  Pupil abnormalities (non-reactive, fixed pupils, or abnormally shaped pupils).&#xD;
&#xD;
          -  Is pregnant, or is breast feeding, or intend to become pregnant during the study.&#xD;
&#xD;
          -  Concurrent participation or expected participation in an interventional (i.e.,&#xD;
             surgical or pharmaceutical interventional) clinical trial within 14 days prior to&#xD;
             study screening.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>22 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Johnson &amp; Johnson Surgical Vision Clinical Trial</last_name>
    <role>Study Director</role>
    <affiliation>Johnson &amp; Johnson Surgical Vision</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>ACE Eyecare, Inc</name>
      <address>
        <city>Bakersfield</city>
        <state>California</state>
        <zip>93301</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Grupo Oftalmo &amp; Plastico, Centro de Oftalmologia y Cirugia Plastica</name>
      <address>
        <city>El Escal√≥n</city>
        <state>San Salvador</state>
        <country>El Salvador</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>El Salvador</country>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>April 1, 2020</study_first_submitted>
  <study_first_submitted_qc>April 1, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">April 2, 2020</study_first_posted>
  <last_update_submitted>May 21, 2021</last_update_submitted>
  <last_update_submitted_qc>May 21, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 24, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cataract</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Johnson &amp; Johnson Medical Devices Companies have an agreement with the Yale Open Data Access (YODA) Project to serve as the independent review panel for evaluation of requests for clinical study reports and participant level data from investigators and physicians for scientific research that will advance medical knowledge and public health. Requests for access to the study data can be submitted through the YODA project site at http://yoda.yale.edu</ipd_description>
    <ipd_url>http://yoda.yale.edu</ipd_url>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

